$AstraZeneca PLC(AZN)$ AstraZeneca ($AZN) is staging a comeback, jumping ~7% to test key £125 resistance.
The primary catalysts behind the push:
* £7.2M Insider Buy: CEO Pascal Soriot personally purchased 60,000 shares, sending a massive vote of confidence to the market.
* Clinical Momentum: Fresh lung cancer trial progress reaffirmed leadership in high-margin oncology.
* Analyst Upgrades: Deutsche Bank upgraded the stock, while Goldman Sachs hiked its target price on pipeline longevity.
* Fundamental Beat: Builds on a clean Q2 earnings beat ($2.63 core EPS vs. $2.50 consensus).
With executive skin in the game and pipeline execution firing, momentum has firmly flipped back to the bulls.
Comments